Metastatic Uveal Melanoma

Everett, Lesley; Copperman, Thomas S

doi:10.1056/nejmicm1810596

Cited by 9 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…She was diagnosed with MUM on imaging. She underwent palliative enucleation followed by chemotherapy but died 2 months after presentation [7]. This study provides a broader perspective through analysis of 21 patients.…”

Section: Discussionmentioning

confidence: 99%

Uveal melanoma metastatic at initial diagnosis: a case series

Steckler¹,

Francis²,

Shoushtari

et al. 2022

Melanoma Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Uveal melanoma metastatic at initial diagnosis: a case series

Steckler¹,

Francis²,

Shoushtari

et al. 2022

Melanoma Research

View full text Add to dashboard Cite

show abstract

“…The lungs are the most frequent target organs of metastasis in patients with advanced subcutaneous melanoma (16). In contrast, uveal melanoma almost exclusively relapses to the liver, supporting the concept of compatibility of metastatic cells with host stroma (18). Once several metastases have formed, cells from each metastasis seed and reseed other tumors adding considerable complexity to the diversity of metastatic clones (14).…”

Section: Metastasis Of Melanomamentioning

confidence: 87%

Micro RNAs Promoting Growth and Metastasis in Preclinical In Vivo Models of Subcutaneous Melanoma

Weidle

Ausländer

Brinkmann

2020

Cancer Genomics Proteomics

View full text Add to dashboard Cite

During the last years a considerable therapeutic progress in melanoma patients with the RAF V600E mutation via RAF/MEK pathway inhibition and immunotherapeutic modalities has been witnessed. However, the majority of patients relapse after therapy. Therefore, a deeper understanding of the pathways driving oncogenicity and metastasis of melanoma is of paramount importance. In this review, we summarize microRNAs modulating tumor growth, metastasis, or both, in preclinical melanoma-related in vivo models and possible clinical impact in melanoma patients as modalities and targets for treatment of melanoma. We have identified miR-199a (ApoE, DNAJ4), miR-7-5p (RelA), miR-98a (IL6), miR-219-5p (BCL2) and miR-365 (NRP1) as possible targets to be scrutinized in further target validation studies.

show abstract

“…Retinoblastoma is an aggressive and malignant intraocular tumor in infancy and childhood, whereas uveal melanoma (UM) typically occurs in the choroid, iris, and ciliary body, the most common intraocular cancer in adults. [ 121 ] The considerably high mortality rate of retinoblastoma and UM warrant the urgent development of efficacious therapeutics. Currently available medical interventions primarily include enucleation (eye removal), external beam/episcleral plaque radiotherapy, chemoreduction, and chemotherapy.…”

Section: Applications Of Ocular Nanomedicinementioning

confidence: 99%

“…Currently available medical interventions primarily include enucleation (eye removal), external beam/episcleral plaque radiotherapy, chemoreduction, and chemotherapy. [ 121 ] Enucleation is the only suitable approach for advanced retinoblastoma, but surgical lesions result in facial deformities. Radiotherapy can induce various side effects, such as dry eye, which requires permanent eye lubrication.…”

Section: Applications Of Ocular Nanomedicinementioning

confidence: 99%

Ocular Nanomedicine

et al. 2022

View full text Add to dashboard Cite

Intrinsic shortcomings associated with conventional therapeutic strategies often compromise treatment efficacy in clinical ophthalmology, prompting the rapid development of versatile alternatives for satisfactory diagnostics and therapeutics. Given advances in material science, nanochemistry, and nanobiotechnology, a broad spectrum of functional nanosystems has been explored to satisfy the extensive requirements of ophthalmologic applications. In the present review, the recent progress in nanosystems, both conventional and emerging nanomaterials in ophthalmology from state-of-the-art studies, are comprehensively examined and the role of their fundamental physicochemical properties in bioavailability, tissue penetration, biodistribution, and elimination after interacting with the ophthalmologic microenvironment emphasized. Furthermore, along with the development of surface engineering of nanomaterials, emerging theranostic methodologies are promoted as potential alternatives for multipurpose ocular applications, such as emerging biomimetic ophthalmology (e.g., smart electrochemical eye), thus provoking a holistic review of "ocular nanomedicine." By affording insight into challenges encountered by ocular nanomedicine and further highlighting the direction of future studies, this review provides an incentive for enriching ocular nanomedicine-based fundamental research and future clinical translation.

show abstract

Metastatic Uveal Melanoma

Cited by 9 publications

References 0 publications

Uveal melanoma metastatic at initial diagnosis: a case series

Uveal melanoma metastatic at initial diagnosis: a case series

Micro RNAs Promoting Growth and Metastasis in Preclinical In Vivo Models of Subcutaneous Melanoma

Ocular Nanomedicine

Contact Info

Product

Resources

About